Mesothelin Sebagai Biomarker Deteksi Dini Kanker Pankreas
Fauziyyah Nuur Al azizah, Rizki Hanriko
Abstract
Abstract: Pancreatic cancer is difficult to diagnose at an early stage and generally has a poor prognosis. Surgical resection is the only potentially curing treatment for pancreatic carcinoma. To improve the prognosis of this disease, it is important to detect tumors at an early stage. The lack of sensitive and specific tumor markers for early diagnosis has a major contribution to the poor prognosis. For this reason, it is necessary to make an early diagnosis of pancreatic cancer through a biomarker in the form of mesothelin which can be found in the blood and urine. Mesothelin is a glycoprotein that is expressed in normal mesothelial cells but is overexpressed in pancreatic cancer. How to check mesothelin levels in the blood can use ELISA and for those in the urine can use spectrophotometry. And mesothelin has been shown to increase in early stage cancer and 64% in metastatic cancer. Mesothelin can also be expressed in other organs such as endometrioid adenocarcinoma (59-64%), cervix (25%), pancreas (86-100%), colorectal (28-50%), esophagus (25-46%) and gastric carcinoma (27-58%) but in pancreatic cancer the amount of mesothelin produced is greater. Therefore mesothelin can be an early detection biomarker that is useful for pancreatic cancer
Keywords: biomarkers, mesothelin, blood, urine, overexpression
Downloads
References
American Joint Committee on Cancer, 7th edition, or the Union for International Cancer Control, 7th edition) Lee, E. S. & Lee, J. M. 2014. Imaging diagnosis of pancreatic cancer: a state‑of‑the-art review. World J. Gastroenterol.; 20(4): 7864–7877.
Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. 2001. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res;7(12):3862–8
Bond-Smith G, Banga N, Hammond TM, Imber CJ. 2012. Pancreatic adenocarcinoma. Br Med J. 344(2):e2476
Coleman WB, Tsongalis GJ. 2002. The molecular basis of human cancer Totowa, NJ: Humana Press
Fabian Mc.Johnston.2009. Circulating Mesothelin Protein and Cellular anti-Mesothelin Immunity in Patients with Pancreatic Cancer Makawita S, Dimitromanolakis A Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP. 2013. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer;13(3):404.
Gupta MK, Arciaga R, Bocci L, Tubbs R, Bukowski R, Deodhar SD. 1985. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer;56(2): 277–83
Harinck, F. et al. 2015. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals.
He, J. et al.2014. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford);16(1): 83–90.
International Agency for research on cancer, Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.
Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statis-tics. CA Cancer J Clin. 60(1): 277-300
Johnston FM, Tan MC, Tan BR, Porembka MR, Brunt EM, Linehan DC, Simon PO, Plambeck- Suess S, Eberlein TJ, Hellstrom KE, Hellstrom I, Hawkins WG, Goedegebuure P. 2009. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res. 15(3): 6511-6518
Jacobetz, M. A. et al. 2013. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. ; 62(1): 112–120.
Komite Penanggulangan Kanker Nasional. 2015. Panduanpenatalaksanaankanker payudara. Jakarta: Kementerian Kesehatan Republik Indonesia.
Lin Zhu, Yiling Liu, Guangyuan Chen 2014 Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis
Okano K, Suzuki Y. 2014. Strategies for early detection of resect-able pancreatic cancer. World J Gastroenterol; 20(32): 11230-11240
Padmomartono F Soemanto. 2009. Tumor Pankreas. Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi V. Interna Publishing. Jakarta, Indonesia
Purnomosari D, Indrayani UD, Irianiwati, Sulistyoningrum DC. 2016. Plasma DNA as a potential biomarker for pancreatic cancer detection. J Med Sci.;48(4):200-5.
Ritts RE, Pitt HA. 1998. CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am;7(1):93–101
Sopha SC, Gopal P, Merchant NB, Revetta FL, Gold DV, Washington K, ShiC.2013. Diagnostic and therapeutic implications of a novel immunohis-tochemical panel detecting duodenal mucosa linvasion by pancreatic ductal adenocarcino-ma. Int J Clin Exp Pathol. 6(4): 2476-86
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin.; 65(2): 5–29.
Widyastuti R, Adiputra PAT, Maliawan S. 2013. pancreatic core needle biopsy. E-jurnal Medika Udayana.;2(2):334-44.
3.png){kind=logo}
